Filing Details
- Accession Number:
- 0001714899-23-000029
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-15 19:01:28
- Reporting Period:
- 2023-02-13
- Accepted Time:
- 2023-02-15 19:01:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1714899 | Denali Therapeutics Inc. | DNLI | Biological Products, (No Disgnostic Substances) (2836) | 463872213 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1724310 | J. Ryan Watts | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-02-13 | 8,815 | $30.09 | 2,239,913 | No | 4 | S | Indirect | See footnote |
| Common Stock | Acquisiton | 2023-02-13 | 25,000 | $0.68 | 2,264,913 | No | 4 | M | Indirect | See footnote |
| Common Stock | Disposition | 2023-02-13 | 25,000 | $30.08 | 2,239,913 | No | 4 | S | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See footnote |
| No | 4 | M | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2023-02-13 | 25,000 | $0.00 | 25,000 | $0.68 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,195,617 | 2025-08-20 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 188,437 | Direct |
Footnotes
- Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.95 to $30.24 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 19,697 restricted stock units held by the Reporting Person.
- The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.26 per share. Upon request by the Commission staff, the Issuer, or asecurityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Includes 188,437 RSUs.
- The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.
Billionaire Hedge Funds
